Hepatitis B Virus Hbsag Surface Protein Antigen vs Nivolumab

## Hepatitis B Virus Hbsag Surface Protein Antigen vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Hepatitis B Virus Hbsag Surface Protein Antigen** and **Nivolumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Hepatitis B Virus Hbsag Surface Protein Antigen — N/A; Nivolumab — 27 days.

## Chemical Properties

**Type**: Hepatitis B Virus Hbsag Surface Protein Antigen — Vaccine component; Nivolumab — Antibody.